Objectives: Although the benefit of magnesium sulfate to prevent cerebral palsy in antenatal on very preterm infants has been shown, there is still reluctance to use it. The aim of this study was to conduct an assessment of our practice using magnesium sulfate to prevent cerebral palsy at Rouen University Hospital to report its feasibility and safety in order to spread its use.
Methods: Unicentric and retrospective study, at the University Hospital of Rouen, between January and June 2014. All patients who delivered before 33 weeks or considered at risk of imminent delivery before 33 weeks were included (n=86).
Results: Among the patients who delivered before 33 weeks (n=82), a magnesium sulfate loading dose was administrated in 91.5% of cases. Treatment was mainly established and monitored by midwives (98.6%), usually in the delivery room (82.4%), and with an average duration of administration of 8.9±17.5hours. The treatment had to be stopped in a patient who presented bradypnea associated with impaired consciousness.
Conclusion: Our study shows that magnesium sulfate can easily be prescribed in clinical practice.
Keywords: Cerebral palsy; Magnesium sulfate; Paralysie cérébrale; Prematurity; Prématurité; Sulfate de magnésium.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.